PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT

PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT

On Wednesday, PharmaDrug Inc. PHRX LMLLF, a company researching DMT and other psychedelics for medical purposes, announced a new clinical trial agreement with Johns Hopkins University, one of the leading research institutions in the space.

The research will encompass a clinical study comparing the psychological and neural effects of N,N-dimethyltryptamine (DMT) with an undisclosed comparator molecule–presumably psilocybin, based on the university’s research record into psychedelics.

The trial stands as part of PharmaDrug’s intention to become a leader in DMT-derived medicines. The company has already received an “orphan drug designation” by the FDA for DMT in the prevention of ischemia-reperfusion injury in patients undergoing solid organ transplantation.  

For its part, Johns Hopkins University is leveraging the booming “psychedelics rush” to advance research into the field. Last week, the university signed a five-year research agreement with  Mydecine Innovations Group MYCO MYCOF to study the application of psychedelics molecules and therapies in smoking cessation.

Terms Of The Deal: As per the agreement, PharmaDrug will gain an exclusive option to obtain worldwide, royalty-bearing commercialization licenses to all rights derived from the study’s results.

The research will take place in the university’s Center for Psychedelic and Consciousness Research at the faculty of psychiatry and behavioral sciences, and will be led by Dr. Frederick S. Barrett, with support from Dr. Sandeep Nayak and Dr. Roland Griffiths.

The researchers will use psychological assessment tools as well as MRI and EEG to characterize any acute and persisting subjective, affective, cognitive and neural dose-dependent effects for both drugs in human subjects.

Photo by Pete Godfrey on Unsplash

Posted In: Johns Hopkins UniversitypsychedelicsCannabisPenny StocksMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.